

AbbVie Pipeline Update

February 7, 2020



abbvie

AbbVie R&D Pipeline

Select Pipeline Assets and Programs

Phase 1	Phase 2	Registrational / Phase 3	Submitted
<ul style="list-style-type: none"> ■ ABBV-157 (RORγT) ■ ABBV-154 (TNF-Steroid ADC) ■ ABBV-151 (GARP+TGFβ1): Solid Tumor ■ ABBV-155 (Bcl-xLi ADC): Solid Tumor ■ ABBV-181 (PD-1): Solid Tumor ■ ABBV-321 (EGFR ADC): Solid Tumor ■ ABBV-368 (OX40): Solid Tumor ■ ABT-165 (DLL4/VEGF): Solid Tumor ■ ABBV-621 (TRAIL): Solid/Heme Tumor ■ ABBV-744 (BET): Heme Tumor ■ ABBV-927 (CD40): Solid Tumor ■ ABBV-CX-2029* (CD71): Solid/Heme Tumor ■ ABBV-647* (PTK7 ADC): NSCLC ■ ABBV-011 (SEZ6 ADC): SCLC ■ Venclexta* (Bcl-2): ALL ■ Venclexta* (Bcl-2): Solid Tumor ■ CCW702* (CD3-PSMA): Prostate Cancer ■ CLBR001/SWI019* (sCAR-T): Heme Tumor ■ TNB-383B* (CD3-BCMA): MM ■ TTX-030* (CD39): Solid Tumor ■ ABBV-0805* (α-Synuclein): PD ■ AL002* (TREM2): AD ■ AL003* (CD33): AD ■ ABBV-4083 (TylAMac): Filarial Diseases 	<ul style="list-style-type: none"> ■ Skyrizi* (IL-23): Atopic Derm ■ Skyrizi* (IL-23): HS ■ ABBV-3373 (TNF-steroid ADC) ■ ABBV-599 (BTK/JAK): RA ■ ABBV-599 (BTK/JAK): SLE ■ Ravagalimab (CD40): UC ■ Imbruvica* (BTK): Solid Tumors ■ Venclexta* (Bcl-2): MDS ■ Teliso-V (cMet ADC): NSCLC ■ ABBV-8E12* (Tau): AD ■ Elezanumab (RGMa): MS ■ ABBV-2222/ABBV-3067 (CFTR-C1/CFTR-P): Cystic Fibrosis ■ Elagolix* (GnRH): PCOS 	<ul style="list-style-type: none"> ■ Rinvoq (JAK 1): PsA ■ Rinvoq (JAK 1): CD ■ Rinvoq (JAK 1): Atopic Derm ■ Rinvoq (JAK 1): UC ■ Rinvoq (JAK 1): GCA ■ Rinvoq (JAK 1): AS ■ Rinvoq (JAK 1): Axial SpA ■ Skyrizi* (IL-23): CD ■ Skyrizi* (IL-23): UC ■ Skyrizi* (IL-23): PsA ■ Imbruvica* (BTK): 1L cGvHD ■ Imbruvica* (BTK): 1L FL ■ Imbruvica* (BTK): 1L MCL ■ Imbruvica* (BTK): R/R MCL ■ Imbruvica* (BTK): R/R FL/MZL ■ Imbruvica* (BTK): 1L CLL ■ Veliparib (PARP): NSCLC ■ Veliparib (PARP): BRCA Breast Cancer ■ Veliparib (PARP): 1L Ovarian Cancer ■ Venclexta* (Bcl-2): 1L CLL ■ Venclexta* (Bcl-2): 1L AML ■ Venclexta* (Bcl-2): AML Maintenance ■ Venclexta* (Bcl-2): R/R MM t(11;14) ■ Navitoclax (Bcl-2/Bcl-xL): Myelofibrosis ■ ABBV-951 (dopamine receptor): PD ■ Elagolix* + Hormonal Add-Back (GnRH): Endometriosis 	<ul style="list-style-type: none"> ■ Elagolix* (GnRH): Uterine Fibroids (US)
			<div style="border: 1px solid black; padding: 5px; width: fit-content; margin: 0 auto;"> Recently Approved </div>
			<ul style="list-style-type: none"> ■ Rinvoq: RA (US, EU, JPN) ■ Skyrizi*: Ps (US, EU, JPN) ■ Venclexta*: 1L CLL (US) ■ Imbruvica* + Gazyva: 1L CLL (US)
			<ul style="list-style-type: none"> ■ Oncology ■ Immunology ■ Neuroscience ■ Targeted Investment

As of February 7, 2020

*Partnered Asset: Partnership Summary Below:

Imbruvica jointly developed and commercialized with Janssen Biotech; Elagolix developed in cooperation with Neurocrine Biosciences; Venclexta developed by AbbVie and Roche, commercialized by AbbVie and Genentech, a member of the Roche Group; Skyrizi developed in cooperation with Boehringer Ingelheim; ABBV-8E12 developed in cooperation with C₂N Diagnostics; ABBV-0805 developed in cooperation with BioArctic; CCW702 / CLBR001 / SWI019 developed by Calibr in a first-in-patient trial and AbbVie holds option to license the program; TNB-383B developed by TeneoOne through Phase 1 and AbbVie holds exclusive right to acquire TeneoOne; AL002/AL003 developed by Alector through Phase 2 and AbbVie holds option for additional development and commercialization; TTX-030 developed by Tizona Therapeutics through Phase 1b and AbbVie has option to lead global development and commercialization; ABBV-2029 developed in cooperation with CytomX Therapeutics; ABBV-647 developed in cooperation with Pfizer.

AbbVie's Recently Launched Medicines Will Expand Into Numerous Important New Disease Areas

Current Approved Indications

Future Disease Areas



- Psoriasis

- Psoriatic Arthritis
- Crohn's Disease
- Ulcerative Colitis
- Atopic Dermatitis
- Hidradenitis Suppurativa



- Rheumatoid Arthritis

- Atopic Dermatitis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Non-radiographic Axial SpA
- Crohn's Disease
- Ulcerative Colitis
- Giant Cell Arteritis



- 1L and r/r CLL
- 1L AML unfit

- AML (1L fit, r/r)
- MM w/ t(11;14)
- MDS
- MCL
- Solid Tumors



- Endometriosis

- Uterine Fibroids
- PCOS

~\$3.2Bn in 2020



New Indications Represent Significant Growth Opportunity

Healthy and Productive Pipeline

Existing Therapies Expanding into Important New Areas



PsA AD
CD HS
UC



AD CD
PsA UC
AS GCA
AxSpA



AML MCL
MM MDS
Solid Tumors



1L MCL
1L cGvHD
FL



UF
PCOS

abbvie

Launching New Assets

Navitoclax

- Current therapies provide symptom relief, with minimal impact on underlying course of the disease
- Compelling POC data illustrate opportunity to transform the treatment of myelofibrosis
- Potential for accelerated approval in 2022

ABBV-951

- Innovative, subcutaneous delivery system for L-dopa / C-dopa prodrug
- Represents a transformational improvement to current treatments for advanced PD
- Potential to significantly broaden addressable patient population beyond those treated with Duopa today

Veliparib

- Developed to safely combine with chemo earlier in treatment paradigm, as well as to expand into non-BRCA deficient tumors
- BRCA breast and 1L ovarian cancers represent a several hundred-million-dollar opportunity for our oncology franchise

Anticipated POC Readouts from Early-Stage Pipeline

- **ABBV-3373** (TNF/steroid ADC) RA Ph2
- **ABBV-599** (JAK/BTK) RA Ph2
- **Ravagalimab** (ABBV-323; CD40) UC Ph2
- **ABBV-157** (ROR γ t) Ps Ph1
- **Teliso-V** (cMet ADC) Solid Tumor Ph2
- **ABBV-155** (Bcl-xLi ADC) Solid Tumor Ph1
- **ABBV-927** (CD40 agonist) Ph1
- **Elezanumab** (RGMa) MS Ph2
- **ABBV-8E12** (Tau) AD Ph2
- **Venclexta** Solid Tumor Ph1
- **ABBV-368** (OX40) Ph1
- **ABBV-621** (TRAIL) Ph1
- **ABBV-647** (PTK7 ADC) Ph1
- **ABBV-011** (SEZ6 ADC) Ph1
- **TNB-383B** (CD3-BCMA) Ph1
- **ABBV-321** (EGFR ADC) Ph1
- **TTX-030** (CD39) Ph1
- **ABBV-151** (GARP+TGFb1) Ph1
- **ABBV-2029** (CD71) Ph1
- **ABBV-599** (JAK/BTK) SLE Ph2
- **ABBV-2222/ABBV-3067** CF Ph2
- **Elagolix** (GnRH) PCOS Ph2
- **ABBV-467** (MCL-1) Ph1
- **ABBV-744** (BET) Ph1
- **ABBV-184** (Survivin-CD3) Ph1
- **Scripts** (DUPA-CD3) Ph1
- **Harpoon** (Survivin-CD3) Ph1
- **Harpoon** (BCMA-CD3)
- **Calibr** (CD19 sCAR-T) Ph1
- **AL002** (TREM2) AD Ph1
- **AL003** (CD33) AD Ph1

2020

2021

2022

Anticipated Key Pipeline Events

	2020	2021	
Regulatory Approvals	Imbruvica ECOG Approval (1L CLL vs. FCR) Venclexta 1L CLL (EU) Elagolix UF	Imbruvica 1L cGvHD Venclexta 1L AML (EU) Veliparib 1L Ovarian Cancer Veliparib BRCA Breast Cancer Rinvoq PsA Rinvoq AD Rinvoq AS Elagolix + Hormonal Add-Back EM	
Regulatory Submissions	Imbruvica 1L cGvHD (iNTEGRATE) Venclexta 1L AML unfit (EU) Veliparib 1L Ovarian Cancer Veliparib BRCA Breast Cancer Rinvoq PsA Rinvoq AD Rinvoq AS Elagolix + Hormonal Add-Back EM	Imbruvica + Venclexta r/r MCL (SYMPATICO) Imbruvica + Venclexta 1L CLL (CAPTIVATE) Imbruvica r/r FL/MZL (SELENE) ABBV-951 PD Skyrizi CD Skyrizi PsA Navitoclax R/R MF	
Ph3/Registrational Data Readouts	Skyrizi Ph3 CD induction (MOTIVATE) Skyrizi Ph3 PsA (KEEPSAKE2) Skyrizi Ph3 Ps H2H vs Cosentyx Rinvoq Ph3 PsA Rinvoq Ph3 Atopic Derm Venclexta Ph3 AML unfit (VIALE-A; VIALE-C) Imbruvica + Venclexta Ph2 1L CLL (CAPTIVATE) Imbruvica Ph3 1L cGvHD (iNTEGRATE)	Imbruvica Ph3 1L MCL (SHINE) Imbruvica Ph3 r/r FL/MZL (SELENE) Imbruvica + Venclexta Ph3 r/r MCL (SYMPATICO) Imbruvica + Venclexta Ph3 1L CLL (GLOW) Venclexta + Imbruvica Ph3 1L CLL (CLL13) Venclexta Ph3 3L+ MM t(11;14) (CANOVA) ABBV-951 Ph3 PD	
Ph3/Registrational Study Starts	Venclexta Ph3 AML fit Venclexta Ph3 MDS Navitoclax Ph3 1L and r/r MF Skyrizi Ph3 UC	Venclexta Ph3 r/r MM t(11;14) w/ Darzalex Venclexta Ph3 Solid Tumors Skyrizi Ph3 AD Skyrizi Ph3 HS Ravagalimab (ABBV-323; CD40) Ph3 UC	
Early-Stage POC Data Readouts	ABBV-3373 (TNF/Steroid ADC) RA Ph2 ABBV-599 (JAK/BTK) RA Ph2 Ravagalimab (ABBV-323; CD40) UC Ph2 ABBV-157 (ROR γ t) Ps Ph1 Teliso-V (cMet ADC) Solid Tumor Ph2 ABBV-155 (Bcl-xLi ADC) Solid Tumor Ph1	ABBV-927 (CD40 Agonist) Ph1 ABBV-368 (OX40) Ph1 ABBV-647 (PTK7 ADC) Ph1 ABBV-011 (SEZ6 ADC) Ph1 TNB-383B (CD3-BCMA) Ph1 ABBV-321 (EGFR ADC) Ph1 TTX-030 (CD39) Ph1 Venclexta Solid Tumor Ph1 ABBV-621 (TRAIL) Ph1	ABBV-151 (GARP+TGF β 1) Ph1 ABBV-2029 (CD71) Ph1 ABBV-599 (JAK/BTK) SLE Ph2 ABBV-8E12 (Tau) AD Ph2 Elezanumab (RGMa) MS Ph2 ABBV-2222/ABBV-3067 (CFTR-C1/CFTR-P) CF Ph2 Elagolix (GnRH) PCOS Ph2

abbvie